Oxford Vacmedix announce results of successful Phase 1 trial of OVM-200

The Phase 1 trial has met both primary and secondary endpoints and additionally early observations of clinical efficacy have been seen.

Oxford, UK – 21st April 2026

Oxford Vacmedix (OVM), the UK biotech company developing novel immunotherapies to treat cancer, is delighted to announce the successful completion of the Phase 1 trial of OVM-200. The primary endpoint for safety has been met as well as the secondary endpoints for immune response and dose selection. In addition, there are early observations of clinical efficacy in NSCLC and in prostate cancer.

This Phase 1 clinical trial of OVM-200 is a multicentre, open-label, first-in-human evaluation of OVM-200, an immunotherapy developed using Oxford Vacmedix's Recombinant Overlapping Peptide (ROP) therapeutic platform. 36 Patients with advanced NSCLC (non-small cell lung cancer), ovarian cancer, or prostate cancer and with no HLA restrictions, were treated in the trial. The results show:

- **Excellent Safety Profile** (primary endpoint): OVM-200 is very well tolerated with no serious adverse drug reactions or no dose-limiting toxicities. The only adverse effects were Grade 1 injection-site reactions.
- **Very strong Immunogenicity** (secondary endpoint): the immune response for both antibodies and for T cells were very strong even in an advanced Stage IV patient population. The immune responses data conclusively demonstrates the dual mode of action of the ROP technology.

- **Therapeutic Dose established** (secondary endpoint) based on the immune response, the 2mg dose was chosen for Phase 1b with expanded immunisations of up to 11 doses of 2mg being used.

- **Early observations of clinical efficacy** with stable disease in NSCLC and PSA response in prostate cancer.

Professor Shisong Jiang, founder and Chief Scientific Officer of Oxford Vacmedix, said:

"We are delighted to be able to confirm these results for this Phase 1 trial of OVM-200 and with this first step toward providing accessible immunotherapy for all patient types. This progress has only been possible through the participation of the patients in the trial and the dedication of the staff in the clinics."

Oxford Vacmedix UK
The Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK
T +44 (0)1865 742087 **E** enquiries@oxfordvacmedix.com www.oxfordvacmedix.com

William Finch, Chief Executive Officer of Oxford Vacmedix, said:

> *"This completion of the clinical trial of OVM-200 marks an important milestone for the company and shows the potential of the ROP technology. We are very pleased to have reached this significant inflection point and are already in discussion with Series B investors to fund Phase 2 trials for OVM-200."*

END

For more information or to express an interest in investing in Series B please contact:

William Finch, CEO, Oxford Vacmedix
T: +44 (0)1865 784074 | M: +44(0)7769 903711 | E: wfinch@oxfordvacmedix.com

Dr Nam Park, Chief Business Officer, Oxford Vacmedix
T: +44 (0)1865 784074 | M: +44(0)7932 613938 | E: npark@oxfordvacmedix.com

Notes to Editor

About Oxford Vacmedix

Oxford Vacmedix UK Ltd, based at the Oxford Science Park, UK, is a biotech company spun out from the University of Oxford's Department of Oncology. The company is utilising the novel proprietary platform technology of recombinant overlapping peptides (ROPs) invented by Professor Shisong Jiang. ROPs have been validated as a technology to stimulate broad and strong T cell and antibody immunity therefore forming a good platform for therapeutic immunotherapy and diagnostics in cancer and infectious diseases.

The technology uses the ROP technology to design and develop therapeutic cancer immunotherapies and diagnostics with the potential for increased efficacy, lower costs, simpler regulatory pathways and synergy when used in combination with other immune oncology (IO) agents. The company has extensive contacts and collaborations in China through Changzhou Bioscience Group (CBIG) that is using the ROP platform for diagnostics in both cancer and in infectious diseases.

OVM is developing two lead immunotherapies, OVM-100 and OVM-200, focusing on unmet clinical need. OVM-100 is an HPV vaccine targeted at cervical cancer, and OVM-200 represents a new type of vaccine utilising survivin to target solid tumours including prostate, ovarian and non-small cell lung cancer (NSCLC). Both immunotherapies will be tested as single agents and in combination with IO agents. OVM has a strong pipeline, with a diagnostic for anti-microbial resistance being tested and one other cancer immunotherapy for pancreatic cancer also in preclinical development.

The company is currently seeking Series B funding to advance OVM-200 to Phase 2 and OVM-100 into Phase 1 trials, as monotherapy and in combination. In addition, the option of using mRNA delivery with the ROP technology will be explored.

For more information: http://www.oxfordvacmedix.com